CSF Markers of Oxidative Stress Are Associated with Brain Atrophy and Iron Accumulation in a 2-Year Longitudinal Cohort of Early MS
暂无分享,去创建一个
P. Dušek | M. Kalousová | B. Srpova | D. Horáková | T. Uher | J. Krasensky | M. Vaněčková | K. Levová | A. Burgetová | L. Lambert | M. Vejrazka | Romana Burgetova | Libuse Nosková | K. Levova | Libuše Nosková | Andrea Burgetová
[1] V. Fleischer,et al. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort , 2022, Neurology: Neuroimmunology & Neuroinflammation.
[2] F. Barkhof,et al. Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis , 2022, Multiple sclerosis.
[3] J. Riolo,et al. Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-world study is associated with disability progression , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.
[4] C. D’Mello,et al. Expression of antioxidant enzymes in lesions of multiple sclerosis and its models , 2022, Scientific Reports.
[5] Jack A. Reeves,et al. Susceptibility networks reveal independent patterns of brain iron abnormalities in multiple sclerosis , 2022, NeuroImage.
[6] P. Dušek,et al. Oxidative Stress Markers in Cerebrospinal Fluid of Newly Diagnosed Multiple Sclerosis Patients and Their Link to Iron Deposition and Atrophy , 2022, Diagnostics.
[7] D. Arnold,et al. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials , 2022, Frontiers in Immunology.
[8] P. Klivényi,et al. Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations , 2022, International journal of molecular sciences.
[9] K. Mucha,et al. Peroxiredoxins as Markers of Oxidative Stress in IgA Nephropathy, Membranous Nephropathy and Lupus Nephritis , 2021, Archivum Immunologiae et Therapiae Experimentalis.
[10] P. Dušek,et al. Age-related magnetic susceptibility changes in deep grey matter and cerebral cortex of normal young and middle-aged adults depicted by whole brain analysis. , 2021, Quantitative imaging in medicine and surgery.
[11] Alaa Abdelghani,et al. Serum malondialdehyde as a lipid peroxidation marker in multiple sclerosis patients and its relation to disease characteristics. , 2021, Multiple sclerosis and related disorders.
[12] O. Ciccarelli,et al. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis , 2021, Neurology.
[13] M. Dwyer,et al. Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI , 2020, Human brain mapping.
[14] R. Benedict,et al. Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross‐Sectional Structural MRI Study , 2020, Journal of magnetic resonance imaging : JMRI.
[15] M. Ramanathan,et al. Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis , 2020, Diagnostics.
[16] Shaojie Shi,et al. Oxidative Stress Marker Aberrations in Multiple Sclerosis: A Meta-Analysis Study , 2020, Frontiers in Neuroscience.
[17] E. Stern,et al. Regional microglial activation in the substantia nigra is linked with fatigue in MS , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[18] J. Lötjönen,et al. Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis , 2020, Frontiers in Neurology.
[19] P. Dušek,et al. Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis , 2020, BioMed research international.
[20] L. Kappos,et al. Monitoring of radiologic disease activity by serum neurofilaments in MS , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[21] M. Mori,et al. Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder , 2020, Clinical and experimental immunology.
[22] C. Enzinger,et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes , 2020, Nature Communications.
[23] E. Havrdová,et al. Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis , 2020, Multiple sclerosis.
[24] D. Hunt,et al. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case–control studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[25] Phillip G. D. Ward,et al. Longitudinal evaluation of iron concentration and atrophy in the dentate nuclei in friedreich ataxia , 2019, Movement disorders : official journal of the Movement Disorder Society.
[26] A. Traboulsee,et al. Increased mean R2* in the deep gray matter of multiple sclerosis patients: Have we been measuring atrophy? , 2018, Journal of magnetic resonance imaging : JMRI.
[27] X. Montalban,et al. Multiple sclerosis: clinical aspects , 2018, Current opinion in neurology.
[28] M. Maciejczyk,et al. Redox Balance, Antioxidant Defense, and Oxidative Damage in the Hypothalamus and Cerebral Cortex of Rats with High Fat Diet-Induced Insulin Resistance , 2018, Oxidative medicine and cellular longevity.
[29] Oliver Speck,et al. A robust multi-scale approach to quantitative susceptibility mapping , 2018, NeuroImage.
[30] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[31] J. Wolff,et al. Synaptic pathology in the cerebellar dentate nucleus in chronic multiple sclerosis , 2017, Brain pathology.
[32] C Langkammer,et al. Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis , 2017, American Journal of Neuroradiology.
[33] Robert Zivadinov,et al. Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain , 2017, NeuroImage: Clinical.
[34] W. Brück,et al. Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation , 2017, International journal of molecular sciences.
[35] Dan Wu,et al. MRICloud: Delivering High-Throughput MRI Neuroinformatics as Cloud-Based Software as a Service , 2016, Computing in Science & Engineering.
[36] Yan Zhang,et al. Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM) , 2016, Journal of magnetic resonance imaging : JMRI.
[37] Christian Enzinger,et al. Dynamics of brain iron levels in multiple sclerosis , 2015, Neurology.
[38] R. Bowtell,et al. Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: A 7 Tesla MRI study , 2015, Journal of magnetic resonance imaging : JMRI.
[39] Simon Hametner,et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[40] Antonio Ayala,et al. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal , 2014, Oxidative medicine and cellular longevity.
[41] O. Ciccarelli,et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[42] Ferdinand Schweser,et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.
[43] Massimo Filippi,et al. Association between pathological and MRI findings in multiple sclerosis , 2012, The Lancet Neurology.
[44] Bernhard Hemmer,et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis , 2012, NeuroImage.
[45] G. Ferretti,et al. Peroxidation of lipoproteins in multiple sclerosis , 2011, Journal of the Neurological Sciences.
[46] Hellmut Merkle,et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. , 2011, Brain : a journal of neurology.
[47] A. Iolascon,et al. Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in β-thalassemic erythropoiesis , 2011, Haematologica.
[48] H. Lassmann,et al. Oxidative damage in multiple sclerosis lesions , 2011, Brain : a journal of neurology.
[49] D. Horáková,et al. Multiple Sclerosis and the Accumulation of Iron in the Basal Ganglia: Quantitative Assessment of Brain Iron Using MRI T2 Relaxometry , 2010, European Neurology.
[50] M. Keleş,et al. Effect of Corticosteroid Therapy on Serum and CSF Malondialdehyde and Antioxidant Proteins in Multiple Sclerosis , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.